期刊
PROTEOMICS CLINICAL APPLICATIONS
卷 2, 期 4, 页码 556-570出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.200780082
关键词
capillary electrophoresis; diagnosis; mass spectrometry; prostate carcinoma; urine
资金
- NCI NIH HHS [P01 CA104106-02, P01 CA104106-01A2, P01 CA104106-04, P01 CA104106-03, P01 CA104106] Funding Source: Medline
- NIGMS NIH HHS [R01 GM080148-02, R01 GM080148, T32 GM008349, T32 GM008349-20, R01 GM080148-01A1] Funding Source: Medline
Only 30% of patients with elevated serum prostate specific antigen (PSA) levels who undergo prostate biopsy are diagnosed with prostate cancer (PCa). Novel methods are needed to reduce the number of unnecessary biopsies. We report on the identification and validation of a panel of 12 novel biomarkers for prostate cancer (PCaP), using CE coupled MS. The biomarkers could be defined by comparing first void urine of 51 men with PCa and.35 with negative prostate biopsy. In contrast, midstream urine samples did not allow the identification of discriminatory molecules, suggesting that prostatic fluids may be the source of the defined biomarkers. Consequently, first void urine samples were tested for sufficient amounts of prostatic fluid, using a prostatic fluid indicative panel (informative polypeptide panel; IPP). A combination of IPP and PCaP to predict positive prostate biopsy was evaluated in a blinded prospective study. Two hundred thirteen of 264 samples matched the IPP criterion. PCa was detected with 89% sensitivity, 5 1% specificity. Including age and percent free PSAto the proteomic signatures resulted in 91% sensitivity, 69% specificity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据